Physiologic basis endocrine therapy prostatic cancer Advances understanding hypothalamic-pituitary gonadal regulation development pharmaceutical agents castrate state minimal morbidity selection method androgen ablation patient stage adenocarcinoma prostate patient preference cost therapeutic outcomes medical castration orchiectomy equivalent addition androgen receptor patient regimen knowledge impact mortality rate modest cost significant Further manipulation androgen production action patients resistant cancer unlikely disease progression mortality rate efforts development effective chemotherapy disease 